Presystemic metabolism. To a large part not metabolised. No data pointing to CYP-interaction. Two references stating (probable) non-porphyrinogenicity.

(To be edited, initial data ST OCT 04) Prodrug, hydrolyzed to trandoprilate, ACE-inhibitor. Low bioavailability (4-14%) due to incomplete absorbtion and presystemic metabolism. 36-95% of the aborbed dose is excreted in unchanged form by the kidneys. South African list: use with care. French list: authorized.

Less common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, diarrhoea and obstipation.

Uneventful use reported in 3 patients with acute porphyria.